FASN and breast carcinoma: For these experiments, we selected Fasnall, a commercially available selective FASN inhibitor that has been shown to exert anti-proliferative effects in several different breast cancer cell lines, including MCF-7, MDA-MB-468, BT474 and SKBR3 [25].